Pet-ct in lymphoma

PET-CT in lymphoma: what it is and how it detects active disease

PET-CT in lymphoma is an advanced hybrid imaging examination that combines positron emission tomography (PET) with high-resolution computed tomography (CT) in a single scanning session. Lymphomas are cancers of the lymphatic system, originating in lymphocytes that populate the lymph nodes, spleen, thymus, bone marrow, and other organs. Because malignant lymphoma cells divide rapidly, they consume substantially higher amounts of glucose than resting healthy cells. By injecting a tiny, harmless quantity of a radioactive glucose analogue called 18F-fluorodeoxyglucose (18F-FDG), clinicians can visualise and measure this elevated metabolic activity throughout the entire body.

To understand what is pet-ct in lymphoma, one must look at how nuclear medicine combines functional biochemistry with cross-sectional anatomy. Standard CT imaging shows the physical dimensions and shape of lymph nodes, but it cannot differentiate between active malignant cells and benign inflammation or inactive scar tissue. PET-CT merges the metabolic "hotspots" captured by the PET detectors directly onto detailed CT cross-sections. For international patients considering pet-ct in lymphoma in Turkey, modern nuclear medicine departments provide rapid access to advanced digital scanning systems. This guide explains how the examination works, what clinical guidelines confirm about its diagnostic accuracy, approximate costs compared with the UK, US, and Germany, and what to expect during your diagnostic stay. For patients exploring oncology care abroad, see our wider guide to oncology treatments in Turkey.

Get my free quote

How does 18F-FDG PET-CT work in lymphoma evaluation?

The examination follows a structured clinical pathway designed to produce sharp, quantifiable images while ensuring patient comfort and safety. Upon arrival at the nuclear medicine department, your identity and clinical history are verified, and your blood glucose is tested via a fingerprick. If your blood glucose is within an acceptable range, an intravenous cannula is placed in a peripheral vein, usually in your arm.

You then receive the radiotracer injection. The 18F-FDG molecule enters cells through transmembrane glucose transporter proteins (principally GLUT-1 and GLUT-3), where the intracellular enzyme hexokinase phosphorylates it into FDG-6-phosphate. Unlike natural glucose, FDG-6-phosphate cannot continue through the glycolytic pathway; it becomes trapped inside the lymphoma cells in direct proportion to their metabolic rate. Following the injection, you rest in a quiet, temperature-regulated room for approximately 60 minutes. This uptake period allows the tracer to circulate and clear from the bloodstream into tissues while minimising uptake in voluntary muscles.

You are then escorted into the scanner room and positioned comfortably on the scanner couch. The examination proceeds in two coordinated stages. First, a low-dose or diagnostic CT scan captures anatomical coordinates and provides tissue attenuation correction data. Immediately afterwards, the PET component detects pairs of 511 keV gamma photons emitted when positrons from decaying fluorine-18 annihilate with local electrons. Sophisticated reconstruction algorithms coregister the metabolic signals onto the anatomical slices. The actual acquisition inside the scanner tunnel takes between 18 and 25 minutes, covering the body typically from the skull base to the mid-thighs.

Does PET-CT in lymphoma work accurately to guide staging and response?

Patients frequently ask does pet-ct in lymphoma work effectively across all disease stages. High-level clinical evidence and international consensus guidelines confirm that it does. Under the Lugano Classification—the global reference standard established by international haematology and oncology societies—18F-FDG PET-CT is the established imaging modality for baseline staging, interim response assessment, and post-treatment evaluation in FDG-avid lymphomas. These include classical Hodgkin lymphoma and aggressive non-Hodgkin subtypes such as diffuse large B-cell lymphoma (DLBCL).

At initial baseline staging, PET-CT demonstrates greater sensitivity and specificity than stand-alone contrast-enhanced CT. It frequently reveals unexpected nodal disease or extranodal involvement in the spleen, liver, and bone marrow without requiring an invasive bone marrow trephine biopsy in most patients with Hodgkin lymphoma. Studies indicate that baseline PET-CT alters the assigned clinical stage or initial treatment plan in 15% to 30% of lymphoma cases, ensuring patients receive appropriately matched systemic therapies from the outset.

During treatment, an interim PET-CT (often performed after two to four cycles of systemic chemotherapy) evaluates early chemosensitivity. This allows oncologists to identify patients whose disease responds rapidly and who may benefit from de-escalated therapy to minimise long-term organ toxicity, as well as those with refractory disease who require an early transition to alternative regimens. However, PET-CT has defined clinical limitations. It cannot differentiate between malignant glucose consumption and active bacterial or fungal infections, granulomatous conditions like sarcoidosis, or recent surgical wound inflammation. Furthermore, some indolent lymphoma subtypes exhibit low baseline FDG avidity, requiring alternative diagnostic strategies.

PET-CT in lymphoma cost in Turkey compared with the UK, US and Germany

Understanding the factors that influence the overall pet-ct in lymphoma cost helps patients budget effectively when considering diagnostic appointments abroad. Across European private medical centres, imaging costs vary depending on scanner technology, cyclotron access, and medical staffing. The figures below provide realistic approximate cost ranges per scan, rather than fixed clinic quotes.

Several clinical elements influence what changes the pet-ct in lymphoma price. Scanners equipped with digital time-of-flight (TOF) detectors and higher slice-count CT components command higher operational fees. The inclusion of intravenous iodinated contrast media for full diagnostic contrast-enhanced CT increases both pharmacy and nursing costs. Package arrangements in Turkish hospital networks typically encompass the radiopharmaceutical dose, nursing care, scanner operational time, dual-reading interpretation by a specialist nuclear medicine physician and radiologist, digital DICOM files on CD or secure USB, and translated English reports. Multi-trip packages may also include airport transfers and dedicated international patient coordination.

Get my free quote

PET-CT, contrast-enhanced CT or MRI for lymphoma assessment?

No single imaging modality answers every clinical question in lymphoma management. Clinicians select modalities based on the histopathological subtype, the clinical stage of treatment, and patient-specific factors such as kidney function or pregnancy. The table below compares the primary imaging modalities used in lymphoma evaluation.

While contrast-enhanced CT remains widely accessible, its primary drawback in lymphoma care is its inability to assess metabolic viability. Following chemotherapy, residual lymph node masses often persist for months or years. Contrast CT measures only physical size and cannot discern whether the residual mass contains living cancer cells or inert fibrotic tissue. PET-CT resolves this ambiguity by demonstrating whether viable cells continue to consume glucose. Whole-body diffusion-weighted MRI serves as a non-ionising option particularly valuable when radiation avoidance is paramount.

Which lymphoma subtypes benefit most from PET-CT imaging?

The clinical utility of PET-CT depends heavily on the histological subtype of lymphoma diagnosed by tissue biopsy. Tumours characterised by rapid lymphocyte proliferation display intense FDG uptake, making PET-CT exceptionally reliable for initial staging and post-treatment monitoring.

Subtypes with routinely high FDG avidity include:

• Classical Hodgkin lymphoma: Displays consistently intense tracer uptake in nodular sclerosis, mixed cellularity, and lymphocyte-depleted subtypes.
• Diffuse large B-cell lymphoma (DLBCL): The most common aggressive non-Hodgkin lymphoma, exhibiting strong glucose consumption across primary and extranodal sites.
• Burkitt lymphoma and lymphoblastic lymphoma: Highly proliferative haematological malignancies where rapid metabolic staging is essential.
• Follicular lymphoma: Although traditionally classified as an indolent lymphoma, the majority of cases show sufficient baseline avidity to allow accurate Lugano staging.
• Mantle cell lymphoma: Most variants show moderate to high FDG uptake, aiding in staging and tracking extranodal spread.

Conversely, subtypes such as chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and marginal zone lymphomas (including MALT lymphoma) frequently exhibit low or variable tracer uptake. In these diseases, a negative PET scan does not exclude microscopic disease. However, if a patient with known indolent lymphoma suddenly develops an intensely avid focal mass, PET-CT can identify suspected histological transformation (such as Richter transformation) to aggressive DLBCL, guiding targeted biopsy. While routine screening for cancer detects broad abnormalities, PET-CT provides functional characterisation for diagnosed haematological cancers. Specialised diagnostic pathways, such as early detection of malignant diseases for women or comprehensive diagnosis for ovarian cancer, similarly integrate multi-parametric imaging with histopathology to establish clear stages.

What do PET-CT results show: understanding SUV and the Deauville scale

Radiology reports for lymphoma PET-CT rely on standardised quantitative metrics and validated visual scoring systems to eliminate ambiguity between treating centres. Understanding these terms helps patients make sense of their written diagnostic findings.

The Standardised Uptake Value (SUV) is a semi-quantitative calculation that reflects radiotracer concentration within a given region of interest, adjusted for the patient's body mass and injected dose. The maximum SUV (SUVmax) represents the highest metabolic activity within a tumour. While higher SUVmax figures generally reflect more aggressive cellular turnover, baseline SUV values vary widely between individuals and cannot be used in isolation to diagnose cancer.

For response assessment during or after chemotherapy, international guidelines utilise the Deauville 5-point scale, which compares residual tumour uptake against standard internal reference tissues:

• Score 1: No uptake above background noise.
• Score 2: Uptake less than or equal to the mediastinum (blood pool).
• Score 3: Uptake greater than the mediastinum but less than or equal to normal liver tissue.
• Score 4: Uptake moderately higher than the liver at any disease site.
• Score 5: Uptake markedly higher than the liver, or any new lesion consistent with lymphoma.

In clinical practice, Deauville scores 1, 2, and 3 generally indicate a complete metabolic response to treatment, confirming that active malignancy has been cleared. Scores 4 and 5 indicate residual active disease or treatment failure, prompting consideration of second-line therapy or consolidated radiotherapy. Regarding before-and-after expectations, post-treatment PET scans reassure patients by demonstrating that lingering physical swellings observed on physical exam or CT are metabolically inactive fibrotic tissue rather than persistent malignancy.

Who is a suitable candidate, and who requires special preparation?

Candidates for lymphoma PET-CT include adults and older children with confirmed or suspected lymphoma requiring baseline staging, interim chemotherapy response evaluation, restaging following therapy completion, or investigation of clinical relapse. However, strict physiological criteria must be met before tracer administration.

Blood glucose regulation represents the most critical preparation factor. Because circulating serum glucose competes directly with 18F-FDG for cell surface transporters, elevated blood sugar dramatically reduces tracer uptake into tumours while increasing background muscle signal. Patients must have fasting blood glucose levels strictly below 11.0 mmol/L (approximately 200 mg/dL). Patients with diabetes require individualised preparation protocols regarding oral hypoglycaemic agents or morning insulin dosing.

Fasting and dietary instructions are rigorous. Patients must consume a high-protein, zero-carbohydrate meal the evening before and fast completely for four to six hours prior to the appointment, though plain unflavoured water is encouraged. Strenuous muscular exercise, running, and heavy lifting must be avoided for 24 to 48 hours beforehand to prevent physiological tracer uptake in skeletal muscle groups. Pregnancy represents a strong relative contraindication due to foetal radiation exposure; imaging is deferred or substituted with MRI unless life-saving maternal staging is urgently required. Breastfeeding mothers must express and discard breast milk for 24 hours after the injection until the radiotracer has fully decayed.

Your scan appointment in Turkey and recovery step by step

Many international patients choose pet-ct in lymphoma Turkey programmes because of shorter appointment wait times and modern scanning infrastructure. Planning your trip requires understanding the sequence of appointments and post-scan steps.

A typical diagnostic visit requires two to three days in Turkey. On the day of your scan, you arrive at the clinic having observed the required fasting period. The clinical team performs a blood glucose check, inserts the cannula, and administers the 18F-FDG injection. During the 60-minute uptake phase, you rest quietly in an individual uptake room without talking, chewing gum, or reading on your phone, as sensory and muscular activity can cause unwanted tracer uptake in the head, neck, and vocal cords. You then transfer to the scanner room for the 20 to 25-minute scan. After the technologist verifies image quality, the cannula is removed and you can leave the department.

Unlike surgical interventions, pet-ct in lymphoma recovery involves no physical downtime or post-operative healing period. You can immediately eat your normal diet and resume standard non-strenuous daily activities. You will be instructed to drink 1.5 to 2 litres of water throughout the remainder of the day to accelerate the excretion of the radiotracer through the urinary system. As a standard safety precaution, you should maintain distance from pregnant women and young infants for 12 to 24 hours after your injection. By the second day, your written report and DICOM image disc are ready for review with your oncologist.

Get my free quote

Risks, radiation exposure and safety considerations

PET-CT is a non-invasive diagnostic examination with a well-established safety profile, but it does involve exposure to ionising radiation. Clinical governance organisations including the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the UK National Health Service (NHS) mandate that all examinations adhere to the ALARA principle (As Low As Reasonably Achievable).

The total radiation effective dose from a whole-body oncology PET-CT scan generally ranges between 7 and 15 millisieverts (mSv). This dose combines the internal radiation from the 18F-FDG radiopharmaceutical (approximately 4 to 7 mSv) with the external radiation from the CT component (approximately 3 to 8 mSv, depending on whether low-dose localisation or full diagnostic contrast CT is selected). To put this in perspective, 10 mSv is roughly equivalent to three to four years of natural environmental background radiation. In the context of cancer staging, the clinical benefits of accurate disease mapping far outweigh the minor statistical risk of radiation-induced secondary effects decades later.

Allergic reactions to 18F-FDG are exceptionally rare, occurring in fewer than one in 100,000 administrations, as the tracer contains only nanogram quantities of glucose analogue. If an iodinated intravenous contrast agent is administered during the CT acquisition, standard contrast risks apply: mild sensations of warmth or metallic taste are common, while minor allergic urticaria or transient renal stress occur in a small percentage of individuals. Disclosing pre-existing kidney disease, asthma, or contrast allergies allows the team to adopt protective hydration protocols or omit intravenous CT contrast when appropriate.

How to choose an imaging centre in Turkey and key questions to ask

Selecting an accredited, technologically capable imaging department ensures your PET-CT scan meets the standards required by your home oncology team. Look for hospital-affiliated nuclear medicine departments that hold national accreditation from the Turkish Ministry of Health and international certifications such as JCI (Joint Commission International) or ISO. The facility should operate modern multi-detector or digital PET-CT scanners with time-of-flight technology, which deliver high spatial resolution and enhanced lesion detection at reduced radiation doses.

Be alert to common clinical red flags. Avoid clinics that fail to provide detailed pre-scan dietary instructions or neglect to check your blood glucose before administering the tracer. Be cautious of centres that supply only compressed summary image sheets rather than full DICOM data files, or facilities that promise same-hour results without providing a formal dual-signed radiological report adhering to Lugano staging guidelines.

Before confirming your diagnostic appointment, consider asking the following questions:

• What generation and specification of PET-CT scanner will be used for my lymphoma imaging?
• Does the appointment include a full diagnostic contrast-enhanced CT or a low-dose attenuation CT?
• Will the final report be authored by a qualified nuclear medicine specialist and structured around the Lugano classification and Deauville scale?
• Will I receive a complete digital copy of my scan in uncompressed DICOM format on CD, USB, or via secure cloud transfer?
• What is the clinic protocol if my fasting blood glucose is elevated above 11.0 mmol/L on the morning of the scan?
• How many business days are required to deliver the formal medical report translated into English?

To understand the steps from your initial enquiry to receiving a full radiology report, learn how our service works, and submit your medical summary for an obligation-free evaluation on our free quote page.

Get my free quote

Conditions treated with PET-CT in Lymphoma

Hospitals with Oncology in Turkey

Academic Hospital

Üsküdar, Istanbul

MoHHealth Tourism Licence+2

Get Free Quote

Lokman Hekim Istanbul Hospital

Pendik, Istanbul

JCIMoH+2

Get Free Quote

View all

Frequently asked questions